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Abstract
In February and September each year the World Health Organisation (WHO) recommends 
influenza viruses to be included in influenza vaccines for the forthcoming winters in the Northern 
and Southern Hemispheres respectively. These recommendations are based on data collected by 
National Influenza Centres (NIC) through the Global Influenza Surveillance and Response System 
(GISRS) and a more detailed analysis of representative and potential antigenically variant 
influenza viruses from the WHO Collaborating Centres for Influenza (WHO CCs) and Essential 
Regulatory Laboratories (ERLs). This article provides a detailed summary of the antigenic and 
genetic properties of viruses and additional background data used by WHO experts during 
development of the recommendations for the 2012 Southern Hemisphere influenza vaccine 
composition.
1. Introduction
In contrast to many other vaccines, influenza vaccines are frequently updated so as to be 
most effective against newly evolving human influenza viruses that are likely to circulate in 
the following influenza season. WHO convenes technical consultations (vaccine 
composition meetings (VCM)) twice a year to provide guidance to national public health 
authorities and vaccine manufacturers on the viruses to be included in trivalent influenza 
vaccines for the following influenza seasons in the Northern and Southern Hemispheres. The 
committee assembled by WHO comprises representatives from six WHO Collaborating 
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Centres (Melbourne, Australia; Beijing, China; Tokyo, Japan; London, United Kingdom; 
Atlanta, USA; Memphis, USA) and four Essential Regulatory Laboratories (ERL) 
(Therapeutic Goods Administration (TGA), Australia; National Institute of Infectious 
Diseases (NIID), Japan; National Institute for Biological Standards and Control (NIBSC), 
UK; Food and Drug Administration (FDA), USA), with observers from several H5 
Reference Laboratories, WHO National Influenza Centres (NICs) and other expert groups. 
In a previous publication [1], the main responsibilities of the WHO committee were 
described. The committee focuses on the geographic spread and epidemiological, antigenic 
and genetic characteristics of the most recently circulating influenza viruses in order to 
assess which are likely to predominate in the forthcoming season. Additionally, sera panels 
from individuals who received seasonal trivalent inactivated vaccines are tested to measure 
the presence of antibodies to recent influenza viruses. National and international regulatory 
agencies make the final decision about which influenza viruses are to be used in influenza 
vaccines to be licensed in their country.
In the present report we describe the basis for the selection of vaccine viruses recommended 
by the WHO for use in the 2012 Southern Hemisphere influenza season. This report 
describes only those data that were available at the time of the WHO VCM held September 
26–28, 2011, in Geneva, Switzerland. The recommended viruses for use in the 2012 
Southern Hemisphere influenza season were:
– An A/California/7/2009 (H1N1)pdm09-like virus
– An A/Perth/16/2009 (A(H3N2)-like virus
– A B/Brisbane/60/2008-like virus
2. Influenza Activity, February – September 2011
Influenza activity between the previous WHO Consultation on the Composition of Influenza 
Vaccines in February 2011 [2] and September 2011 [3] was reported by NICs and collated in 
the WHO FluNet database (see http://www.who.int/flunet). During this period, influenza 
was active worldwide and reported in Africa, the Americas, Asia, Europe and Oceania. Co-
circulation of influenza A(H1N1) 2009 pandemic (subsequently referred to as 
A(H1N1)pdm09 as recommended by WHO [4]), A(H3N2) and influenza B viruses 
continued, to infect humans with the predominant circulating virus type and sub-type 
varying between countries and regions. In general, influenza activity was low or moderate 
compared with recent years. Influenza activity maps for the period February to September 
2011 along with graphs showing the number of influenza viruses detected, typed and 
subtyped by the GISRS laboratories are presented in Fig. 1. During this time the majority of 
global influenza activity and detection occurred in the Northern Hemispherein February and 
March. At the time of the consultation, data collected from the GISRS laboratory network 
showed that of the influenza viruses collected from February to September 2011, 
approximately 40% were A(H1N1)pdm09, 16% were A(H3N2), 14% were not subtyped 
influenza A and 30% were influenza B.
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3. Overview of antigenic and genetic characteristics of the viruses
For the Consultation, WHO CCs performed detailed antigenic analyses on approximately 
4400 influenza viruses (Table 1). Viruses were collected from March 2011 to the end of 
August 2011 and recovered from either clinical specimens or virus isolates provided by over 
70 NICs and other laboratories within and outside of GISRS. Antigenic characterisation was 
carried out predominantly in haemagglutination inhibition (HI) assays using viruses isolated 
and propagated in either mammalian tissue culture cells (most frequently Madin-Darby 
canine kidney cells (MDCK), or MDCK-SIAT-1 cells engineered to express increased levels 
of α2–6 sialyl transferase [5]) or in embryonated hens’ eggs. HI assays using turkey or 
guinea pig red blood cells (RBC) were performed to compare the reactivity of cultured 
viruses with post-infection ferret antisera raised against egg or cell grown reference, vaccine 
and recent representative viruses [6]. A subset of viruses also underwent genetic 
characterisation. Genetic analyses routinely focused on the sequencing of the 
haemagglutinin (HA) (the complete HA or the HA1 coding region) and neuraminidase (NA) 
genes with full genome sequencing performed on a smaller subset of viruses. Gene 
sequencing provides the molecular basis for observed antigenic variation and phylogenetic 
analysis of HA and NA genes defines the genetic relatedness of antigenic variants. The 
initial phylogenetic tree of the HA1 domain nucleotide sequences of each type or subtype 
was constructed with the PhyML software package version 3.0 [7] using GTR+I+Γ4. For 
this analysis the general time-reversible model with the proportion of invariant sites and the 
gamma distribution of among-site rate variation with four categories was estimated from the 
empirical data, determined by ModelTest [8] as the evolutionary model. GARLI v0.961 [9] 
was run on the best tree from PhyML for 2 million generations to optimise tree topology and 
branch lengths for each virus type or sub-type. The list of virus gene sequence accession 
numbers and their originating laboratories used in this report are listed in Tables S8a–d.
The combination of antigenic and genetic data is used routinely to identify emergent 
antigenic variants. Antigenic cartography [10] was used to visualize the HI data. These 
results are used to identify virus variants with future epidemic potential, and to be 
considered as potential vaccine candidates.
As discussed previously, the behaviour of A(H3N2) viruses in HA and HI assays has 
changed in recent years and their antigenic analyses have become more complex [1]. In 
particular, guinea pig RBC are now preferred for antigenic characterisation of current 
A(H3N2) viruses in HA and HI assays. To control for the possible participation of the virus 
NA in the agglutination of RBC, HI assays can also be performed in the presence of 
oseltamivir [11]. Virus neutralisation (plaque reduction and micro-neutralisation) assays 
were performed in addition to HI tests for a subset of A(H3N2) viruses.
In addition to antigenic studies using post-infection ferret antisera, human serum panels 
obtained pre- and post- vaccination with seasonal influenza vaccine formulations were used 
to assess current vaccine coverage against representative recently circulating viruses. . 
Serum panels for adults), older adults) and paediatric populations received from Australia, 
China, Japan, the UK and the USA were tested where available.
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4. A(H1N1)pdm09 viruses
The vast majority of influenza A(H1N1)pdm09 viruses collected February - August 2011 
remained antigenically closely related to the vaccine virus A/California/7/2009. The results 
of a typical HI assay are presented in Table 2 (see also supplementary Table S1). Only two 
viruses in this table (A/Argentina/656/2011 and A/Sapporo/163/2011) demonstrated more 
than a 4-fold reduction in HI titre compared with the homologous titre obtained using post-
infection ferret antiserum raised against the A/California/7/2009 vaccine virus. It should be 
noted that the A/Argentina/656/2011 and A/Sapporo/163/2011 viruses have amino acid 
(AA) substitutions G156E and K154E, respectively in their HA molecules. AA substitutions 
in the 153–157 region of the HA were identified in many cell or egg grown A(H1N1)pdm09 
viruses that had low reactivity to the ferret antisera raised against A/California/7/2009 (see 
below) and nucleotide polymorphism is frequently seen within samples in the HA gene 
encoding these amino acids. Notably, more recent A(H1N1)pdm09 viruses from Australia 
demonstrated reduced reactivity with ferret antisera raised against A/California/7/2009 
(Table S1), with many having HA AA substitutions or polymorphisms at positions 153–157. 
A summary of HI test results for A(H1N1)pdm09 viruses from all WHO CCs is shown in 
Table 1.
Genetic analyses of the HA genes of A(H1N1)pdm09 viruses are shown in Fig. 2 (see also 
Fig. S1 that presents a high resolution tree constructed from sequences of >1,600 
A(H1N1)pdm09 isolates collected through GISRS since 2010-01-01). Currently the 
phylogenetic tree of the A(H1N1)pdm09 HA gene can be divided into eight major genetic 
subgroups. At the time of the VCM the majority of recent isolates belonged to subgroups 6 
and 7 with a signature AA substitution of S185T in the HA1. Subgroup 6 viruses, which had 
been circulating worldwide, carry AA substitution D97N. Subgroup 7 viruses, mainly seen 
in Europe, Asia and Oceania, carry the AA substitution A197T and many also carry the AA 
substitution S143G. Subgroup 5 viruses were also found worldwide with signature AA 
substitutions of D97N, R205K, I216V and V249L. Viruses of HA subgroup 4 have not 
circulated widely since early 2011 carry the AA substitution N125D. Subgroup 3 includes 
viruses with AA substitutions A134T and S183P in the HA. Subgroup 2 and 8 share the AA 
substitution A186T. Subgroup 2 includes viruses that had been collected globally, with AA 
substitutions N31D and S162N (which results in the gain of a potential glycosylation site at 
residue 162 of the HA) while subgroup 8 includes viruses collected from Africa with an AA 
substitution of V272A. Lastly genetic subgroup 1 includes early 2011 isolates from Asia and 
North America that carry the AA substitution S128P. Sequences of isolates with 
substitutions at positions 153–157 in the HA do not form a monophyletic group; instead they 
are distributed throughout the phylogenetic tree and appear in nearly all circulating genetic 
groups (Fig. 2). Full genome sequencing has been carried out on viruses from several 
geographic regions and no evidence of reassortment with co-circulating A(H3N2) viruses 
was observed (data not shown).
Antigenic cartography illustrates that the majority of A(H1N1)pdm09 isolates are 
antigenically similar to A/California/7/2009 and cluster together demonstrating little 
antigenic diversity during this period or since 2009 (Fig. 3). Although viruses with 8-fold or 
greater reductions in HI with the A/California/7/2009 ferret antisera cluster together 
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somewhat apart from antigenically similar antigens in the antigenic map, as mentioned 
above they do not form a separate genetic group and are spread throughout the HA 
phylogenic tree (Fig. 3).
Vaccines containing the A/California/7/2009 (H1N1) antigen stimulated anti-HA antibodies 
of similar geometric mean HI titres to the vaccine virus and the majority of representative 
A(H1N1)pdm09 isolates. Fig. S2 summarises human serology data obtained by all WHO 
CCs and ERLs that perform human serology studies. Only two viruses used in human 
serology tests - A/Sapporo/163/2011 and A/South Australia/4/2011 – demonstrated a 50% or 
greater reduction in geometric mean titres (GMT) in HI tests with human sera from 
vaccinees who received the A/California/7/2009 antigen. Both of these viruses also showed 
reduced HI reactivity (4- to 8-fold) with post-infection ferret antisera raised against A/
California/7/2009. Additionally, A/Sapporo/163/2011 is representative of isolates with AA 
substitutions seen in positions 153 through 157 of the HA.
Based on analyses of data presented at the VCM, it was concluded that the observed genetic 
diversity of A(H1N1)pdm09 viruses did not result in changes in their antigenic properties 
and that A/California/7/2009 remained appropriate for the 2012 Southern Hemisphere 
vaccine composition [12].
5. A(H3N2) viruses
Combined data from all WHO CCs using a variety of antigenic assays identified a low 
proportion of February - August 2011 isolates (5%) with greater than 8-fold reduction in 
titre (as compared to the titres of the homologous antigen) to ferret antisera raised against 
the A/Perth/16/2009 vaccine virus (Table 1). Table 3 presents an example of an HI assay 
using guinea pig RBC in the presence of 20 nM oseltamivir. Based on results of both HI (see 
also Table S2) and virus neutralisation (Table S3) assays, it was concluded that the majority 
of A(H3N2) viruses that circulated from February to August 2011 in different parts of the 
world were antigenically closely related to the A/Perth/16/2009 vaccine virus.
A phylogenetic tree for the HA1 of A(H3N2) viruses is presented in Fig. 4 (see also Fig. S3 
that presents a high resolution tree constructed from sequences of >1,000 A(H3N2) isolates 
collected through GISRS since 2010-01-01). A(H3N2) viruses continued to fall into two 
major genetic clades represented by A/Victoria/208/2009 and A/Perth/16/2009. Viruses with 
reduced HI titres to post-infection ferret antisera raised against A/Perth/16/2009 were 
scattered throughout the HA tree and did not form monophyletic groups or share common 
AA substitutions.
The A(H3N2) HA tree can be further divided into seven genetic subgroups. Isolates in the 
smaller A/Perth/16/2009 genetic clade carry signature AA substitutions E62K and N144K 
(leading to the loss of a potential glycosylation site). Within the A/Perth/16/2009 group there 
are subgroups 1 and 2 with several AA substitutions. Subgroup 1 consists mainly of isolates 
from Japan, China and other parts of Asia; many viruses within this subgroup also have 
signature AA substitutions P162S, I260M and R261Q. Subgroup 2 includes early 2011 U.S. 
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isolates with AA substitutions N133D (leading to the loss of a potential glycosylation site), 
R142G, T212A and V213A in the HA1.
The majority of A(H3N2) isolates collected worldwide belong to the A/Victoria/208/2009 
genetic clade, but remain antigenically related to A/Perth/16/2009. Within the A/Victoria/
208/2009 clade, the most commonly circulating subgroups were subgroups 5 and 6, which 
have signature AA substitutions D53N, Y94H, I230V and E280A in HA1. Subgroup 6 
isolates carrying an additional AA substitution, S199A. The remaining isolates in the 
Victoria/208/2009 clade that were in circulation between January 2011 and September 2011 
group formed three smaller subgroups, 3, 4 and 7. Subgroup 3 isolates have a signature AA 
substitution V223I. Within subgroup 3, one cluster of viruses collected from Europe and 
Africa shared substitutions N144D (leading to the loss of a potential glycosylation site) and 
N145S. Another cluster within subgroup 3 isolates collected from Asia and Oceania also 
carry additional AA substitutions A198S and N312S. Subgroup 5 isolates have three AA 
substitutions, T48A, K92R and N312S and subgroup 7 isolates share AA substitution N45S 
(resulting in the gain of a potential glycosylation site).
Vaccines containing influenza A/Perth/16/2009 (H3N2)-like antigen stimulated anti-HA 
antibodies of similar geometric mean HI titres to the vaccine virus and the majority of 
representative A(H3N2) isolates, consistent with results obtained in HI assays with ferret 
antisera (Fig. S4). Among 12 tested A(H3N2) antigens, three (A/Sakai/20/2011 from genetic 
subgroup 5; A/South Australia/3/2011 and A/Sydney/27/2011, both from genetic subgroup 
3) consistently demonstrated a 50% or greater reduction in post vaccination GMT compared 
to A/Perth/16/2009-like vaccine viruses and an 8-fold or greater reduction in HI titre with 
ferret antisera (data not shown).
Based on surveillance data available in September 2011, it was concluded that the A(H3N2) 
component of the 2012 Southern Hemisphere influenza vaccine should continue to be an A/
Perth/16/2009-like virus.
6. Influenza B viruses
There are two lineages of influenza B viruses that show little antigenic cross reactivity, the 
B/Victoria/2/87- and B/Yamagata/16/88 [13]. Viruses from both of these lineages have been 
observed in various proportions in different countries since 1988–89. Only one of these two 
lineages of influenza B virus has been included in trivalent seasonal influenza vaccines.
From January to April 2011 most B viruses reported to WHO belonged to the B/Victoria 
lineage. The analyses of influenza B viruses by HI assays continue to demonstrate that sera 
raised in ferrets infected with egg-grown B viruses may react poorly with cell-grown B 
viruses, prompting the use of cell-grown viruses for serum production in ferrets [1]. In 
addition, influenza B viruses often generate antisera with lower titres than those raised 
against influenza A viruses, some CCs use additional boosting of ferrets potentially 
broadening the cross-reactivity of the antibody response.
Combines HI data from all WHO CCs found only 3% of February - August 2011 isolates 
had reduced HI titres to post-infection ferret antiserum raised against A/Brisbane/60/2008, 
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the current vaccine virus (Table 1) using data combined from all WHO CCs. Table 4 
represents results of a typical HI assay performed using turkey RBC with recent influenza B/
Victoria lineage viruses. These and other data showed that the majority of 2011 influenza B 
viruses were antigenically closely related to the cell grown equivalents of the B/Brisbane/
60/2008 vaccine virus .
The HA genes of recent B/Victoria-lineage viruses fell into six main phylogenetic groups, 
with the vast majority of them falling in group 1 represented by B/Brisbane/60/2008 with 
signature AA substitutions of N75K, N165K and S172P (Fig. 5). (A high resolution tree 
constructed from sequences of >1,000 B/Victoria lineage isolates collected through GISRS 
since 2010-01-01 is shown in Fig. S5). Of the B/Victoria-lineage genetic groups, 2–6, only 
isolates from group 5 have been detected recently; most of these group 5 viruses were 
isolated at the beginning of 2011 in South East Asia and Oceania (Figs 5 and S5). All group 
1 viruses remained antigenically similar to B/Brisbane/60/2008. Small genetic subgroups 
within group 1 were identified including a subgroup with no AA substitutions in HA that 
clustered in the nucleotide tree with contemporary isolates from Africa, Asia and the U.S. 
and a second small subgroup that included isolates collected recently in Asia and South 
America with the HA AA substitution L58P. Many of the recent isolates from China in this 
second subgroup had HA and NA genes from different groups of the B/Victoria-lineage; HA 
genes from the B/Victoria-lineage group 1 and NA genes from HA group 4; the NA of these 
intra-lineage reassortant viruses had additional AA substitutions D384N and A465T (leading 
to the gain of a potential glycosylation site) in the NA compared with viruses that carried 
both the HA and NA gene of group 4. Viruses in the third small subgroup within group 1 
have AA substitution V146I in the HA1. An additional subgroup within group 1 has 
undergone intra-Victoria lineage reassortment inheriting the NA gene from isolates similar 
to those in HA group 3 (represented by B/Uruguay/12/2008), but with additional AA 
substitutions of L73F, S397R and A389T in the NA. The majority of isolates within this 
subgroup have AA substitution V15I in the HA1 and circulated in North and South America 
and Oceania.
B/Yamagata-lineage viruses were detected at low levels in all countries with the exception of 
China where B/Yamagata-lineage viruses comprised over 45% of B viruses detected (data 
not shown). Regional differences in the distribution of B/Yamagata- and B/Victoria-lineages 
were seen between the north and south of China. While B/Yamagata-lineage viruses were 
isolated throughout the country, the majority of B/Victoria-lineage isolates were isolated in 
the south of China.
Most recent B/Yamagata isolates were antigenically distinct from the previous vaccine virus, 
B/Florida/4/2006, and were more closely related to the B/Wisconsin/1/2010 or B/Hubei-
Wujiagang/158/2009 reference viruses (Table 5) and the B/Bangladesh/3333/207 reference 
virus (data not shown). The HA genes of recent B/Yamagata-lineage viruses clustered 
phylogenetically into group 3 with signature AA substitutions S150I, N166Y and G230D 
(see Fig. S6 for a high resolution tree constructed from sequences of over 250 B/Yamagata 
lineage isolates collected since 2010-01-01).
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Data generated by WHO CCs and ERLs showed that the post-vaccination sera obtained from 
people immunized with vaccines containing B/Brisbane/60/2008-like viruses reacted well 
with recent influenza B viruses from the B/Victoria lineage, but less well with B viruses 
from the B/Yamagata lineage (Fig. S7). There was on average only a 23% reduction in post-
vaccination GMTs to the recent B/Victoria lineage viruses compared with those to the 
vaccine virus, whereas the equivalent reduction in post-vaccination GMT to B/Yamagata 
lineage viruses was on average 67%.
Based on the predominance of B/Victoria-lineage viruses in many parts of the world 
throughout the surveillance period covered here, and their antigenic similarity to B/Brisbane/
60/2008, it was concluded that vaccines containing a B/Brisbane/60/2008-like virus 
remained appropriate for the Southern Hemisphere for 2012.
7. Antiviral resistance
The two classes of antiviral drugs currently licensed for the prevention and treatment of 
influenza are the adamantanes or M2 ion channel inhibitors (amantadine and rimantadine) 
and the neuraminidase inhibitors (oseltamivir and zanamivir). More than 99% of 
A(H1N1)pdm09 viruses tested carry the AA substitution S31N in the M2 protein associated 
with resistance to amantadine and rimantadine. There were sporadic detections of 
oseltamivir resistance in A(H1N1)pdm09 viruses due to an H275Y substitution in NA. 
Although the level of resistance to oseltamivir remains low worldwide (~2%, Table 6), 
available data indicate that the proportion of resistant A(H1N1)pdm09 viruses isolated from 
patients not exposed to the drug increased in Australia, Japan, the UK and U.S. compared to 
previous seasons (data not shown). All A(H1N1)pdm09 viruses were sensitive to zanamivir 
(data not shown). More than 99% of A(H3N2) viruses characterised were resistant to 
adamantanes (based on the presence of the M2 protein AA substitution S31N) but all were 
sensitive to neuraminidase inhibitors, oseltamivir (Table 6) and zanamivir (data not shown). 
Over 99% of all B viruses characterized were sensitive to neuraminidase inhibitors 
oseltamivir (Table 6) and zanamivir (data not shown).
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Fig. 1. 
Maps showing peak levels of laboratory confirmed influenza (reported to FluNet) in each 
country with an NIC, for the period February to September 2011: a) A(H1N1)pdm09 
viruses; b) A(H3N2) viruses; c) B viruses. The total number of seasonal and pandemic 
viruses detected by GISRS from February to September 2011 for each type/subtype is 
shown in panels: d) A(H1N1)pdm09; e) A(H3N2); f) B viruses.
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Fig. 2. 
Phylogenetic trees of representative A(H1N1)pdm09 HA1 domain nucleotide sequences 
were constructed with the PhyML software package 3.0 [7] using GTR+I+Γ4 as determined 
by ModelTest [8]. GARLI v0.961 [9] was run on the best tree from PhyML for 2 million 
generations to optimise tree topology and branch lengths. Amino acid substitutions are 
marked on major nodes. Viruses are colour-coded by month of collection as follows: March-
April 2011 in Blue, May 2011 in Green, June – July 2011 in Orange, August 2011 in Pink. 
The current vaccine strain is in Red. Genetic subgroups are labelled 1–8.
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Fig. 3. 
An antigenic map [10] generated from A(H1N1)pdm09 HI data from WHO CCs in Atlanta, 
London, Melbourne and Tokyo from April 2009 – August 2011. Viruses are represented as 
circles, antisera as squares. The current vaccine strain A/California/7/2009 is represented by 
the large green dot, 2011 viruses with 8-fold or greater reductions in HI titres to the A/
California/7/2009 ferret antiserum are in red, the remaining 2011 viruses in blue. The Grid 
indicates a 2-fold dilution in HI titre, 1 unit of antigenic distance [10].
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Fig. 4. 
Phylogenetic trees of representative A(H3N2) HA1 domain nucleotide sequences were 
constructed and annotated as described for Fig. 2. Genetic subgroups are labelled 1–7.
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Fig. 5. 
Phylogenetic trees of representative B/Victoria lineage HA1 domain nucleotide sequences 
were constructed and annotated as described for Fig. 2. Genetic groups are labelled 1–7.
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Table 1
Influenza isolates characterized by hemagglutination inhibition assay by WHO Collaborating Centres 
(samples collected in March – August, 2011)
A(H1N1)pdm09a A(H3N2)b B/Victoriac B/Yamagatad
Total tested 1232 776 1770 598
Low reactors (% of total) 160 (3%) 40 (5%) 53 (3%) 0
aCompared to the A/California/7/2009 vaccine virus
bCompared to the A/Perth/16/2009 vaccine virus
cCompared to the B/Brisbane/60/2008 vaccine virus
dCompared to reference viruses B/Wisconsin/01/2010, B/Hubei-Wujiagang/158/2009 or B/Bangladesh/3333/2007
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Table 6
Frequency of resistance to oseltamivir in isolates or clinical materials collected from March – August, 2011
A(H1N1)pdm09 A(H3N2) B
Samples tested 2135 780 1377
Resistant (%) 48* (2.2%) 0 2a,b (0.1%)
*
H275Y mutation, also confers resistance to Peramivir
a
B/Lyon/CHU/16.432/2011 (B/Victoria lineage): also resistant to Zamamivir and Peramivir
b
B/Kochi/61/2011 (B/Victoria lineage): also resistant to Zanamivir and Peramivir
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